Back to Rare Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT02116764

NCT02116764
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You must be older than 2 years of age.
  • You must already be enrolled in and receiving treatment under a Chronic Granulomatous Disease (CGD) program at the NIAID (a government health research institute).
  • This applies whether or not you have had a blood stem cell transplant (confirm with trial site).

Who may not be able to join:

  • There are no specific exclusion criteria listed in the source information provided (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registry
clinicaltrials_gov
Start date
11 June 2014
Est. completion
2 June 2022

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The primary objective of this protocol is to estimate the 1- year, 2-year and 3-year (and longer if possible) overall survival probabilities post-HCT of CGD subjects born on or after 1988 who receive HCTon or after 1995.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov